000280027 001__ 280027
000280027 005__ 20250824001720.0
000280027 0247_ $$2doi$$a10.1002/mds.30230
000280027 0247_ $$2pmid$$apmid:40395207
000280027 0247_ $$2pmc$$apmc:PMC12273614
000280027 0247_ $$2ISSN$$a0885-3185
000280027 0247_ $$2ISSN$$a1531-8257
000280027 0247_ $$2altmetric$$aaltmetric:177705759
000280027 037__ $$aDZNE-2025-00871
000280027 041__ $$aEnglish
000280027 082__ $$a610
000280027 1001_ $$aSeemann, Jens$$b0
000280027 245__ $$aCapture of Longitudinal Change in Real-Life Walking in Cerebellar Ataxia Increases Patient Relevance and Effect Size.
000280027 260__ $$aNew York, NY$$bWiley$$c2025
000280027 3367_ $$2DRIVER$$aarticle
000280027 3367_ $$2DataCite$$aOutput Types/Journal article
000280027 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755684661_25776
000280027 3367_ $$2BibTeX$$aARTICLE
000280027 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280027 3367_ $$00$$2EndNote$$aJournal Article
000280027 520__ $$aWith disease-modifying drugs for degenerative ataxias on the horizon, ecologically valid measures of gait performance that can detect patient-relevant changes in trial-like time frames are highly warranted.In this 2-year longitudinal study, we aimed to unravel ataxic gait measures sensitive to longitudinal changes in patients' real lives using wearable sensors.We assessed longitudinal gait changes of 26 participants with degenerative cerebellar disease (Scale for the Assessment and Rating of Ataxia [SARA]: 9.4 ± 4.1) at baseline, 1-year, and 2-year follow-up using three body-worn inertial sensors in two conditions: (1) laboratory-based walking (LBW); and (2) real-life walking (RLW). In RLW, a context-sensitive analysis was performed by selecting comparable walking bouts according to macroscopic gait characteristics. Gait analysis focused on measures of spatio-temporal variability, particularly stride length variability, lateral step deviation, and a compound measure of spatial variability (SPCmp).Gait variability measures showed high test-retest reliability in both walking conditions (intraclass correlation coefficient [ICC], ≥0.82). Cross-sectional analyses revealed high correlations of gait measures with ataxia severity (SARA, effect size ρ ≥ 0.75); and with patients' subjective balance confidence (Activity-specific Balance Confidence scale [ABC]: ρ ≥ 0.71). Although SARA showed longitudinal changes only after 2 years, the gait measure SPCmp revealed changes after 1 year with high effect size (rprb = 0.80). Sample size estimation for the gait measure SPCmp showed a required cohort size of n = 42 participants (n = 38; spinocerebellar ataxias [SCA]1/2/3 subgroup) to detect a 50% reduction in progression at 1 year with a hypothetical intervention, compared to n = 147 for SARA at 2 years.Because of their ecological validity and larger effect sizes, real-life gait characteristics represent promising performance measures as outcomes for future treatment trials. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000280027 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280027 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280027 650_7 $$2Other$$abiomarker
000280027 650_7 $$2Other$$acerebellar ataxia
000280027 650_7 $$2Other$$adigital health
000280027 650_7 $$2Other$$areal‐life walking
000280027 650_7 $$2Other$$awearable sensors
000280027 650_2 $$2MeSH$$aHumans
000280027 650_2 $$2MeSH$$aFemale
000280027 650_2 $$2MeSH$$aMale
000280027 650_2 $$2MeSH$$aCerebellar Ataxia: physiopathology
000280027 650_2 $$2MeSH$$aCerebellar Ataxia: complications
000280027 650_2 $$2MeSH$$aLongitudinal Studies
000280027 650_2 $$2MeSH$$aMiddle Aged
000280027 650_2 $$2MeSH$$aAged
000280027 650_2 $$2MeSH$$aWalking: physiology
000280027 650_2 $$2MeSH$$aGait Analysis
000280027 650_2 $$2MeSH$$aGait Disorders, Neurologic: physiopathology
000280027 650_2 $$2MeSH$$aGait Disorders, Neurologic: etiology
000280027 650_2 $$2MeSH$$aReproducibility of Results
000280027 650_2 $$2MeSH$$aDisease Progression
000280027 650_2 $$2MeSH$$aGait: physiology
000280027 7001_ $$aBeyme, Theresa$$b1
000280027 7001_ $$aJohn, Natalie$$b2
000280027 7001_ $$aHarmuth, Florian$$b3
000280027 7001_ $$aGiese, Martin$$b4
000280027 7001_ $$0P:(DE-2719)2810795$$aSchöls, Ludger$$b5$$udzne
000280027 7001_ $$aTimmann, Dagmar$$b6
000280027 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b7
000280027 7001_ $$0P:(DE-2719)9001643$$aIlg, Winfried$$b8
000280027 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.30230$$gVol. 40, no. 7, p. 1343 - 1355$$n7$$p1343 - 1355$$tMovement disorders$$v40$$x0885-3185$$y2025
000280027 8564_ $$uhttps://pub.dzne.de/record/280027/files/DZNE-2025-00871%20SUP.docx
000280027 8564_ $$uhttps://pub.dzne.de/record/280027/files/DZNE-2025-00871.pdf$$yOpenAccess
000280027 8564_ $$uhttps://pub.dzne.de/record/280027/files/DZNE-2025-00871%20SUP.doc
000280027 8564_ $$uhttps://pub.dzne.de/record/280027/files/DZNE-2025-00871%20SUP.odt
000280027 8564_ $$uhttps://pub.dzne.de/record/280027/files/DZNE-2025-00871%20SUP.pdf
000280027 8564_ $$uhttps://pub.dzne.de/record/280027/files/DZNE-2025-00871.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280027 909CO $$ooai:pub.dzne.de:280027$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280027 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810795$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000280027 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000280027 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280027 9141_ $$y2025
000280027 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000280027 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280027 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-16$$wger
000280027 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280027 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000280027 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000280027 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000280027 9201_ $$0I:(DE-2719)5000005$$kAG Schöls$$lClinical Neurogenetics$$x0
000280027 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x1
000280027 980__ $$ajournal
000280027 980__ $$aVDB
000280027 980__ $$aUNRESTRICTED
000280027 980__ $$aI:(DE-2719)5000005
000280027 980__ $$aI:(DE-2719)1210000
000280027 9801_ $$aFullTexts